表紙:遺伝子治療の市場動向・市場シェア・市場規模の予測 (2021-2028年):適応症 (大細胞型B細胞リンパ腫・ベータサラセミアメジャー/SCD)・ベクタータイプ (レンチウイルス・AAV)・地域別
市場調査レポート
商品コード
989688

遺伝子治療の市場動向・市場シェア・市場規模の予測 (2021-2028年):適応症 (大細胞型B細胞リンパ腫・ベータサラセミアメジャー/SCD)・ベクタータイプ (レンチウイルス・AAV)・地域別

Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-cell Lymphoma, Beta-Thalassemia Major/SCD), By Vector Type (Lentivirus, AAV), By Region, And Segment Forecasts, 2021 - 2028

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 180 Pages | 納期: 2-10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.86円
遺伝子治療の市場動向・市場シェア・市場規模の予測 (2021-2028年):適応症 (大細胞型B細胞リンパ腫・ベータサラセミアメジャー/SCD)・ベクタータイプ (レンチウイルス・AAV)・地域別
出版日: 2021年02月03日
発行: Grand View Research, Inc.
ページ情報: 英文 180 Pages
納期: 2-10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の遺伝子治療の市場規模は予測期間中20.4%のCAGRで推移し、2028年には100億米ドルの規模に成長すると予測されています。がんの有病率の増加、がんの有効な治療法の欠如、先進的ながん治療薬の臨床試験の推進などの要因が同市場の成長を推進しています。

当レポートでは、世界の遺伝子治療の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、パイプラインの分析、市場規模の推移・予測、適応症・ベクタータイプ・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 調査手法

第3章 市場可変因子・動向・展望

  • 市場動向・展望
  • 市場の分類
  • 市場力学
  • 規制の枠組み
  • 主な取引・戦略的提携
  • パイプライン分析
  • 決済・価格設定モデル
  • SWOT分析
  • ポーターのファイブフォース分析
  • COVID-19:影響分析

第4章 市場予測・動向分析:適応症別

  • 急性リンパ芽球性白血病(ALL)
  • 遺伝性網膜疾患
  • 大細胞型B細胞リンパ腫
  • アデノシンデアミナーゼ (ADA) -欠損重症複合免疫不全症(SCID)
  • 黒色腫
  • ベータサラセミアメジャー/鎌状赤血球症(SCD)
  • 頭頸部扁平上皮がん
  • 末梢動脈疾患
  • 脊髄性筋萎縮症(SMA)
  • その他

第5章 市場予測・動向分析:ベクタータイプ別

  • レンチウイルスベクター
  • アデノ随伴ウイルス(AAV)ベクター
  • レトロウイル&ガンマレトロウイルスベクター
  • 改変単純ヘルペスウイルス
  • アデノウイルスベクター
  • 非ウイルスプラスミド

第6章 市場予測・動向分析:地域・主要国別

  • 市場シェア実績・予測
  • 市場規模の推移・予測
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第7章 企業プロファイル

図表

List of Tables

  • TABLE 1 Ongoing projects for CAR T-cell therapies
  • TABLE 2 Non-viral DNA vectors (non-replicating) in gene therapy trials
  • TABLE 3 Some of the examples of molecules under development based on lentiviral vectors
  • TABLE 4 Molecules in development based on AAV vectors
  • TABLE 5 North America gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 6 North America gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 7 The U.S. gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 8 The U.S. gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 9 Canada gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 10 Canada gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 11 Europe gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 12 Europe gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 13 Asia Pacific gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 14 Asia Pacific gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 15 China gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 16 China gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 17 Japan gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 18 Japan gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 19 Russia gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 20 Russia gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 21 Australia gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 22 Australia gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • TABLE 23 RoW gene therapy market, by indication type, 2017 - 2028 (USD Million)
  • TABLE 24 RoW gene therapy market, by vector type, 2017 - 2028 (USD Million)

List of Figures

  • FIG. 1 Market summary (USD Million)
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Global gene therapy pipeline as of 2017, by phase of trial
  • FIG. 12 Global cancer incidence, as of 2019/2020
  • FIG. 13 Market restraint relevance analysis (Current & future impact)
  • FIG. 14 Gene therapy prices by eligible patients per year
  • FIG. 15 Annual Investment in the CAR-T Space, 2013-2026
  • FIG. 16 Global financings in cell therapy, 2017-2019
  • FIG. 17 Recent and ongoing manufacturing capacity expansions for viral vector and large-scale cell therapies, as of 2017
  • FIG. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 19 Porter's Five Forces Analysis
  • FIG. 20 Gene therapy market: Indication type outlook key takeaways
  • FIG. 21 Gene therapy market: Indication type movement analysis
  • FIG. 22 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2017 - 2028 (USD Million)
  • FIG. 23 Global gene therapy market for inherited retinal disease, 2017 - 2028 (USD Million)
  • FIG. 24 Global gene therapy market for large B-cell lymphoma, 2017 - 2028 (USD Million)
  • FIG. 25 Global gene therapy market for ADA-SCID, 2017 - 2028 (USD Million)
  • FIG. 26 Global gene therapy market for melanoma (lesions), 2017 - 2028 (USD Million)
  • FIG. 27 Global gene therapy market for Beta-Thalassemia Major/SCD, 2017 - 2028 (USD Million)
  • FIG. 28 Global gene therapy market for head & neck squamous cell carcinoma, 2017 - 2028 (USD Million)
  • FIG. 29 Global gene therapy market for peripheral arterial disease, 2017 - 2028 (USD Million)
  • FIG. 30 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2017 - 2028 (USD Million)
  • FIG. 31 Global gene therapy market for other indications, 2017 - 2028 (USD Million)
  • FIG. 32 Gene therapy market vector type outlook: Key takeaways
  • FIG. 33 Gene therapy market: Vector type movement analysis
  • FIG. 34 Global lentivirus-based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 35 Global AAV-based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 36 Global retrovirus vectors-based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 37 Global modified herpes simplex virus vectors -based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 38 Global adenovirus vectors -based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 39 Global plasmids-based gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 40 Regional market place: Key takeaway
  • FIG. 41 Gene therapy regional outlook, 2020 & 2028
  • FIG. 42 North America gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 43 The U.S. gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 44 Canada gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 45 Europe gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 46 Asia Pacific gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 47 China gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 48 Japan gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 49 Russia gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 50 Australia gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 51 RoW gene therapy market, 2017 - 2028 (USD Million)
  • FIG. 52 Strategy framework
目次
Product Code: GVR-2-68038-179-5

Gene Therapy Market Growth & Trends

The global gene therapy market size is expected to reach USD 10.0 billion by 2028 registering a CAGR of 20.4% during the forecast period, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer coupled with the lack of effective treatment for the disease. Constant expansion of cancer genetic studies has deciphered relevant information about cancer-related molecular signatures.

This has driven the clinical trials for advanced cancer therapeutics, thereby driving the market growth. In addition, expansion of this mode of treatment in non-cancer applications with approval of therapies, such as approval of Bluebird Bio's Zynteglo in June 2019 for B-thalassemia and others, demonstrates the shift in the preferences of companies towards other unsaturated segments.

Various universities and institutes are observed to exhibit a broad portfolio in the pipeline, which is anticipated to boost revenue generation in the future. The market is anticipated to witnesses a short-term revenue slowdown due to a shift in focus and delay in product launches. However, initiatives for developing novel trial designs, improving the regulatory environment, and managing the supply chain are expected to play a critical role in minimizing the impact of the current global crisis.

Gene Therapy Market Report Highlights

  • Viral vectors have proven their efficiency as a method for effective gene deliveries. As a result, a substantial number of research communities and biotechnology companies have designed their gene therapy programs based on viral vectors
  • Moreover, most of currently FDA-secured products involve the use of viral vectors, which contributes to the dominance of the viral vectors segment
  • Due to the approval and huge success of lentivirus-based Kymriah and retrovirus-based Yescarta, retrovirus and lentivirus are also among the key revenue-generating segments
  • Cancer has led the revenue flow in the market over the past few years and is expected to maintain its dominance in the forecast period
  • The presence of approved products for various cancer forms including Large B-cell lymphoma, Acute Lymphoblastic Leukemia (ALL), and melanoma has resulted in the dominance of this segment
  • The U.S. is recognized as the hub for clinical trials related to gene therapy. This has significantly impacted the revenue growth of the North America market
  • Also, the success of Yescarta and Kymriah in the U.S. as the first approved CAR-t therapy programs has driven huge investments by various government agencies, sponsors, and key companies in this region
  • Major market participants are partnering with other key stakeholders via signing licensing, commercialization, and development deals to enhance their worldwide business operations
  • For instance, in June 2020, uniQure announced a license agreement with CSL Behring for the commercialization of hemophilia B gene therapy

Table of Contents

Chapter 1 Gene Therapy Makret: Executive Summary

  • 1.1 Market Summary

Chapter 2 Gene Therapy Makret: Research Methodology

  • 2.1 Information Procurement
  • 2.2 Information Or Data Analysis
  • 2.3 Market Model
    • 2.3.1 Historic And Base Year Estimates
    • 2.3.2 Forecast Analysis
    • 2.3.3 Study Of Approved Therapies By Disease Incidence
    • 2.3.4 Study Of Approved Therapies By Vector
    • 2.3.5 Region-Wise Approval

Chapter 3 Gene Therapy Makret: Market Variables, Trends, & Scope

  • 3.1 Market Trends & Outlook
  • 3.2 Market Segmentation
  • 3.3 Market Dynamics
    • 3.3.1 Market driver analysis
      • 3.3.1.1 Robust gene therapy pipeline
      • 3.3.1.2 Introduction of technological advancements
      • 3.3.1.3 Increasing investment from the companies and partnerships
      • 3.3.1.4 Growing prevalence of target diseases and increased demand for innovative medicine
    • 3.3.2 Market restraint analysis
      • 3.3.2.1 Absence of effective Diagnosis Framework
      • 3.3.2.2 High prices of gene therapy
    • 3.3.3 Market opportunity analysis
      • 3.3.3.1 Rising investment for adoptive T cell transfer approaches of disease treatment
      • 3.3.3.2 Facility expansion for cell and gene therapies
      • 3.3.3.3 Technological advancements in manufacturing vectors
    • 3.3.4 Market challenge analysis
      • 3.3.4.1 Production capacity challenges
      • 3.3.4.2 Manufacturing challenges pertaining to large-scale production of vectors
  • 3.4 Regulatory Framework
  • 3.5 Major Deals & Strategic Alliances Analysis
    • 3.5.1 Mergers & acquisitions
    • 3.5.2 Collaborations & partnerships
  • 3.6 Pipeline Analysis
  • 3.7 Payment & Pricing Models
    • 3.7.1 Payment models for innovative therapies
  • 3.8 SWOT analysis, by factor (Political & legal, economic, and technological)
  • 3.9 Porter's Five Forces Analysis
  • 3.10 COVID-19 Impact Analysis
    • 3.10.1 Key Market Initiatives
    • 3.10.2 Conclusion

Chapter 4 Gene Therapy Makret: Indication Business Analysis

  • 4.1 Gene therapy market: Indication Movement Analysis
  • 4.2 Acute Lymphoblastic Leukemia (ALL)
    • 4.2.1 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2017 - 2028 (USD Million)
  • 4.3 Inherited Retinal Disease
    • 4.3.1 Global gene therapy market for inherited retinal disease, 2017 - 2028 (USD Million)
  • 4.4 Large B-cell Lymphoma
    • 4.4.1 Global gene therapy market for large B-cell lymphoma, 2017 - 2028 (USD Million)
  • 4.5 Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)
    • 4.5.1 Global gene therapy market for ADA-SCID, 2017 - 2028 (USD Million)
  • 4.6 Melanoma (Lesions)
    • 4.6.1 Global gene therapy market for melanoma (lesions), 2017 - 2028 (USD Million)
  • 4.7 Beta-Thalassemia Major/Sickle Cell Disease (SCD)
    • 4.7.1 Global gene therapy market for Beta-Thalassemia Major/SCD, 2017 - 2028 (USD Million)
  • 4.8 Head & Neck Squamous Cell Carcinoma
    • 4.8.1 Global gene therapy market for head & neck squamous cell carcinoma, 2017 - 2028 (USD Million)
  • 4.9 Peripheral Arterial Disease
    • 4.9.1 Global gene therapy market for peripheral arterial disease, 2017 - 2028 (USD Million)
  • 4.10 Spinal Muscular Atrophy (SMA)
    • 4.10.1 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2017 - 2028 (USD Million)
  • 4.11 Others
    • 4.11.1 Global gene therapy market for Others, 2017 - 2028 (USD Million)

Chapter 5 Gene Therapy Makret: Vector Type Business Analysis

  • 5.1 Gene Therapy Market: Vector Type Movement Analysis
  • 5.2 Gene Therapy Market: Technology Movement Analysis
  • 5.3 Lentiviral Vectors
    • 5.3.1 Global lentivirus-based gene therapy market, 2017 - 2028 (USD Million)
  • 5.4 Adeno-Associated Viral (AAV) Vectors
    • 5.4.1 Global AAV-based gene therapy market, 2017 - 2028 (USD Million)
  • 5.5 RetroVirus & gamma RetroVirus Vectors
    • 5.5.1 Global RetroVirus & gamma RetroVirus vectors-based gene therapy market, 2017 - 2028 (USD Million)
  • 5.6 Modified Herpes Simplex Virus
    • 5.6.1 Global modified herpes simplex virus vectors-based gene therapy market, 2017 - 2028 (USD Million)
  • 5.7 Adenovirus Vectors
    • 5.7.1 Global adenovirus vectors -based gene therapy market, 2017 - 2028 (USD Million)
  • 5.8 Non-viral Plasmid
    • 5.8.1 Global Non-viral plasmid-based gene therapy market, 2017 - 2028 (USD Million)

Chapter 6 Gene Therapy Makret: Regional Business Analysis

  • 6.1 Gene Therapy Market Share, By Region
  • 6.2 Gene Therapy Market: Regional Movement Analysis
  • 6.3 North America
    • 6.3.1 North America Gene therapy market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.2 The U.S.
      • 6.3.2.1 The U.S. gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.3.2.2 The U.S. gene therapy market, by vector type, 2017 - 2028 (USD Million)
    • 6.3.3 Canada
      • 6.3.3.1 Canada gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.3.3.2 Canada gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • 6.4 Europe
    • 6.4.1 Europe gene therapy market estimates and forecast, 2017 - 2028 (USD Million)
  • 6.5 Asia Pacific
    • 6.5.1 Asia Pacific gene therapy market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.5.2 Japan
      • 6.5.2.1 Japan gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.5.2.2 Japan gene therapy market, by vector type, 2017 - 2028 (USD Million)
    • 6.5.3 China
      • 6.5.2.1 China gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.5.2.2 China gene therapy market, by vector type, 2017 - 2028 (USD Million)
    • 6.5.4 Russia
      • 6.5.4.1 Russia gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.5.4.2 Russia gene therapy market, by vector type, 2017 - 2028 (USD Million)
    • 6.5.5 Australia
      • 6.5.5.1 Australia gene therapy market, by indication, 2017 - 2028 (USD Million)
      • 6.5.5.2 Australia gene therapy market, by vector type, 2017 - 2028 (USD Million)
  • 6.6 RoW
    • 6.6.1 RoW gene therapy market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 7 GENE THERAPY MAKRET: COMPANY Profiles

  • 7.1 Company Profiles
    • 7.1.1 REGENXBIO, Inc.
      • 7.1.1.1 Company overview
      • 7.1.1.2 Financial performance
      • 7.1.1.3 Product benchmarking
      • 7.1.1.4 Strategic Initiatives
    • 7.1.2 Oxford BioMedica plc
      • 7.1.2.1 Company overview
      • 7.1.2.2 Financial performance
      • 7.1.2.3 Product benchmarking
      • 7.1.2.4 Strategic Initiatives
    • 7.1.3 Voyager Therapeutics
      • 7.1.3.1 Company overview
      • 7.1.3.2 Financial performance
      • 7.1.3.3 Product benchmarking
      • 7.1.3.4 Strategic Initiatives
    • 7.1.4 Human Stem Cells Institute
      • 7.1.4.1 Company overview
      • 7.1.4.2 Financial performance
      • 7.1.4.3 Product benchmarking
      • 7.1.4.4 Strategic Initiatives
    • 7.1.5 Dimension Therapeutics, Inc.
      • 7.1.5.1 Company overview
      • 7.1.5.1.1 Financial performance
      • 7.1.5.2 Product benchmarking
      • 7.1.5.3 Strategic Initiatives
    • 7.1.6 Bristol-Myers Squibb Company
      • 7.1.6.1 Company overview
      • 7.1.6.1.1 Celgene Corporation
      • 7.1.6.2 Financial performance (Bristol-Myers Squibb)
      • 7.1.6.2.1 Financial performance (Celgene Corporation)
      • 7.1.6.3 Product benchmarking (Bristol-Myers Squibb)
      • 7.1.6.3.1 Product benchmarking (Celgene)
      • 7.1.6.4 Strategic Initiatives
    • 7.1.7 Sanofi
      • 7.1.7.1 Company overview
      • 7.1.7.2 Financial performance
      • 7.1.7.3 Product benchmarking
      • 7.1.7.4 Strategic Initiatives
    • 7.1.8 Applied Genetic Technologies Corporation
      • 7.1.8.1 Company overview
      • 7.1.8.2 Financial performance
      • 7.1.8.3 Product benchmarking
      • 7.1.8.4 Strategic Initiatives
    • 7.1.9 F. Hoffmann-La Roche Ltd.
      • 7.1.9.1 Company overview
      • 7.1.9.1.1 Spark Therapeutics, Inc.
      • 7.1.9.2 Financial performance
      • 7.1.9.2.1 Financial performance
      • 7.1.9.3 Product benchmarking
      • 7.1.9.4 Strategic Initiatives
    • 7.1.10 bluebird Bio, Inc.
      • 7.1.10.1 Company overview
      • 7.1.10.2 Financial performance
      • 7.1.10.3 Product benchmarking
      • 7.1.10.4 Strategic Initiatives
    • 7.1.11 Novartis AG
      • 7.1.11.1 Company overview
      • 7.1.11.1.1 AveXis, Inc.
      • 7.1.11.2 Financial performance
      • 7.1.11.2.1 Financial performance (AveXis)
      • 7.1.11.3 Product benchmarking
      • 7.1.11.4 Strategic Initiatives
      • 7.1.11.4.1 Strategic Initiatives
    • 7.1.12 Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
      • 7.1.12.1 Company overview
      • 7.1.12.2 Financial performance
      • 7.1.12.3 Product benchmarking
      • 7.1.12.4 Strategic Initiatives
    • 7.1.13 UniQure N.V.
      • 7.1.13.1 Company overview
      • 7.1.13.2 Financial performance
      • 7.1.13.3 Product benchmarking
      • 7.1.13.4 Strategic Initiatives
    • 7.1.14 Shire Plc
      • 7.1.14.1 Company overview
      • 7.1.14.2 Financial performance
      • 7.1.14.3 Product benchmarking
      • 7.1.14.4 Strategic Initiatives
    • 7.1.15 Cellectis S.A.
      • 7.1.15.1 Company overview
      • 7.1.15.2 Financial performance
      • 7.1.15.3 Product benchmarking
      • 7.1.15.4 Strategic Initiatives
    • 7.1.16 Sangamo Therapeutics, Inc.
      • 7.1.16.1 Company overview
      • 7.1.16.2 Financial performance
      • 7.1.16.3 Product benchmarking
      • 7.1.16.4 Strategic Initiatives
    • 7.1.17 Orchard Therapeutics
      • 7.1.17.1 Company overview
      • 7.1.17.2 Financial performance
      • 7.1.17.3 Product benchmarking
      • 7.1.17.4 Strategic Initiatives
    • 7.1.18 Gilead Lifesciences, Inc.
      • 7.1.18.1 Company overview
      • 7.1.18.2 Financial Performance
      • 7.1.18.3 Product benchmarking
      • 7.1.18.4 Strategic Initiatives
    • 7.1.19 BENITEC BIOPHARMA
      • 7.1.19.1 Company overview
      • 7.1.19.2 Financial Performance
      • 7.1.19.3 Product benchmarking
      • 7.1.19.4 Strategic Initiatives
    • 7.1.20 Sibiono GeneTech Co., Ltd
      • 7.1.20.1 Company overview
      • 7.1.20.2 Product benchmarking
    • 7.1.21 Shanghai Sunway Biotech Co., Ltd.
      • 7.1.21.1 Company overview
      • 7.1.21.2 Product benchmarking
    • 7.1.22 Gensight Biologics S.A.
      • 7.1.22.1 Company overview
      • 7.1.22.2 Financial performance
      • 7.1.22.3 Product benchmarking
      • 7.1.22.4 Strategic initiatives
    • 7.1.23 Transgene
      • 7.1.23.1 Company overview
      • 7.1.23.2 Financial performance
      • 7.1.23.3 Product benchmarking
      • 7.1.23.4 Strategic initiatives
    • 7.1.24 Calimmune, Inc.
      • 7.1.24.1 Company overview
      • 7.1.24.2 Product benchmarking
      • 7.1.24.3 Strategic initiatives
    • 7.1.25 Epeius Biotechnologies Corp.
      • 7.1.25.1 Company overview
      • 7.1.25.2 Financial performance
      • 7.1.25.3 Product benchmarking
    • 7.1.26 Astellas Pharma Inc.
      • 7.1.26.1 Company overview
      • 7.1.26.2 Audentes Therapeutics, Inc.
      • 7.1.26.2.1 Company overview
      • 7.1.26.3 Financial performance
      • 7.1.26.3.1 Financial performance
      • 7.1.26.4 Product benchmarking
      • 7.1.26.5 Strategic initiatives
    • 7.1.27 American Gene Technologies
      • 7.1.27.1 Company overview
      • 7.1.27.2 Product benchmarking
      • 7.1.27.3 Strategic initiatives
    • 7.1.28 BioMarin Pharmaceuticals, Inc.
      • 7.1.28.1 Company overview
      • 7.1.28.2 Financial performance
      • 7.1.28.3 Product benchmarking
      • 7.1.28.4 Strategic initiatives